ArticleAdvances in radiation oncology
Fractionated stereotactic radiation therapy for intact brain metastases.
Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Single- and hypofractionated stereotactic radiosurgery for large (> 2 cm) brain metastases: a systematic review.Journal of neuro-oncology · 2021Pooled it
- Outcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?BMC cancer · 2026Article
- Comparison of 3 vs 5 Fraction Single Isocenter Radiosurgery for Brain Metastases.Advances in radiation oncology · 2026Article
- Dosimetric evaluation of Ethos 2.0 high-fidelity mode for single-isocenter SRS.Journal of applied clinical medical physics · 2025Article
- Review
- Management of critically located brain metastases in patients with precluded survival using customised double-dose prescription-based, adaptive accelerated staged radiosurgery: a long-term retrospective analysis.Radiation oncology (London, England) · 2025Article
- Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity.Discover oncology · 2024Article
- Association of increasing gross tumor volume dose with tumor volume reduction and local control in fractionated stereotactic radiosurgery for unresected brain metastases.Radiation oncology (London, England) · 2024Article
- Analysis of linear accelerator-based fractionated stereotactic radiotherapy in brain metastases: efficacy, safety, and dose tolerances.Frontiers in oncology · 2024Article
- A single center, inter-observer evaluation of vestibular schwannoma stereotactic radiosurgery and its dosimetric impact.Journal of radiosurgery and SBRT · 2024Article
- Fractionated versus staged gamma knife radiosurgery for mid-to-large brain metastases: a propensity score-matched analysis.Journal of neuro-oncology · 2023Article
- Pretreatment lymphocyte-to-monocyte ratio as a prognostic factor and influence on dose-effect in fractionated stereotactic radiotherapy for oligometastatic brain metastases in non-small cell lung cancer patients.Frontiers in oncology · 2023Article
- Gamma knife icon based hypofractionated stereotactic radiosurgery (GKI-HSRS) for brain metastases: impact of dose and volume.Journal of neuro-oncology · 2022Article
- Outcomes of Hypofractionated Stereotactic Radiotherapy for Small and Moderate-Sized Brain Metastases: A Single-Institution Analysis.Frontiers in oncology · 2022Article
- Plan Quality Assessment of Fractionated Stereotactic Radiotherapy Treatment Plans in Patients With Brain Metastases.Frontiers in oncology · 2022Article
- A single high-dose irradiation changes accumulation of methotrexate and gene expression levels of SLC and ABC transporters in cancer cells.Frontiers in pharmacology · 2022Article
- Single-fraction versus hypofractionated gamma knife radiosurgery for small metastatic brain tumors.Clinical & experimental metastasis · 2021Article
- Hypofractionated frameless gamma knife radiosurgery for large metastatic brain tumors.Clinical & experimental metastasis · 2021Article
- CBCT Verification of SRT for Patients With Brain Metastases.Frontiers in oncology · 2021Article
- Feasibility and potential advantages using VMAT in SRS metastasis treatments.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLimited data exist on fractionated stereotactic radiation therapy (FSRT) for brain metastases. We sought to evaluate the safety and efficacy of FSRT and further define its role in brain metastasis management. METHODS AND MATERIALS: A total of 72 patients were treated with linear accelerator-based FSRT to 182 previously untreated, intact brain metastases. Targets received 25 or 30 Gy in 5 fractions. All targets within the same course received the same prescription regardless of size. Toxicity was recorded per Radiation Therapy Oncology Group central nervous system toxicity criteria.
resultsThe median follow-up was 5 months (range, 1-71 months). The Kaplan-Meier estimate of 12-month local control was 86%. Tumors <3 cm in diameter demonstrated improved 12-month local control of 95% compared with 61% in tumors ≥3 cm (
conclusionsFSRT for brain metastases appears to demonstrate a high rate of local control with minimal risk of severe toxicity. Local control appears to be associated with smaller tumor sizeand a higher prescription dose. FSRT is a viable option for those who are poor single-fraction candidates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.